Abstracts tagged "SLE"

Abstract Number: 604 • 2013 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Is Not Associated With Reduced Cardiovascular Or Lupus Damage Accumulation In a Cross-Sectional Lupus Cohort Study
Maureen A. McMahon¹, Maria Dall'era², Eliza Chakravarty³, Joseph E. Craft⁴, Gary S. Gilkeson⁵, Kenneth C. Kalunian⁶, R. John Looney⁷, Gerald McGwin Jr.⁸ and Meggan Mackay⁹, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Yale University School of Medicine, Internal Medicine, Section of Rheumatology, New Haven, CT, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶UCSD School of Medicine, La Jolla, CA, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Mycophenolate mofetil (MMF) is frequently used for the treatment of lupus. The immune-modulating effects of MMF extend beyond effects on lymphocyte proliferation, and include…
Abstract Number: 34 • 2013 ACR/ARHP Annual Meeting
Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation
Franziska Matzkies¹, Anthony DeFranco², Andrew J. Gross³, Maria Dall'era⁴ and Michelle Hermiston⁵, ¹Medicine- Rheumatology, University of California, San Francisco, San Francisco, CA, ²Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Hematology/Oncology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Autoantibody production is a hallmark of Systemic Lupus Erythematosus (SLE), supporting a central role for B cells in disease pathogenesis. Prior studies have demonstrated…
Abstract Number: 2722 • 2013 ACR/ARHP Annual Meeting
In Vivo Administration Of MiR-146a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, John B. Harley^4,5 and Nan Shen^1,2,6, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: miR-146a as an endogenous regulator plays a critical role in resolving acute inflammation. The risk-associated genetic variant in miR-146a promoter was linked to reduced…
Abstract Number: 1636 • 2013 ACR/ARHP Annual Meeting
Pro-Inflammatory HDL and Subclinical Atherosclerosis Are Associated With Altered Expression Of Epigenetic and Oxidative Stress-Related Gene Transcripts In SLE
Brian Skaggs¹, Bevra H. Hahn², Jennifer M. Grossman³, Elaine Lourenco¹, Isao Matsuura⁴, Lori Sahakian⁵ and Maureen A. McMahon⁶, ¹Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁶Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Premature atherosclerosis is widely recognized as a significant co-morbid condition of systemic lupus erythematosus (SLE), but exact mechanisms are unknown. Although traditional cardiovascular risk…
Abstract Number: 1061 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotypes and Disease Burden Of Discoid Lupus Erythematosus In a Sample Of Systemic Lupus Erythematosus Patients In The Southeastern United States
Leslie Anne Cassidy¹, Gaobin Bao², Charmayne M. Dunlop-Thomas³, S. Sam Lim⁴ and Cristina Drenkard^5,6, ¹Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, ²Medicine, Emory University, Atlanta, GA, ³Medicine Rheumatology, Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ⁵Department of Medicine, Emory University, Atlanta, GA, ⁶Epidemiology, Emory Rollins School of Public Health, Atlanta, GA
Background/Purpose: The rash of discoid lupus erythematosus (DLE) has been reported in 10-25% of patients with systemic lupus erythematosus (SLE). Prior reports suggest that DLE…
Abstract Number: 605 • 2013 ACR/ARHP Annual Meeting
Childhood Lupus Nephritis: Long Term Outcome Of 91biopsy Proven Cases From India
Puja Srivastava¹, Bonnie Abujam², Ramnath Misra¹, Able Lawrence¹, Vikas Agarwal¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Childhood SLE has a higher prevalence of lupus nephritis (LN) as well as proliferative LN than adults. There is ethnic variation in response to…
Abstract Number: 2724 • 2013 ACR/ARHP Annual Meeting
cAMP Responsive Element Modulator (CREM)α Governs CD8 Expression and Contributes to the Generation of CD3⁺CD4^–CD8^– T Cells in Lupus
Christian M. Hedrich¹, José C. Crispín¹, Thomas Rauen¹, Christina Ioannidis¹, Tomohiro Koga², Noe Rodriguez Rodriguez², Sokratis A. Apostolidis³, Vasileios C. Kyttaris² and George C. Tsokos¹, ¹Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: CD3+CD4-CD8- "double negative" T cells are expanded in the peripheral blood of patients with systemic lupus erythematosus (SLE) and lupus-prone mice. Double negative T…
Abstract Number: 1637 • 2013 ACR/ARHP Annual Meeting
IKZF1 Modulates PP2Ac Expression Through An Intronic Binding Site
Kamalpreet Nagpal¹, Katsue S. Watanabe² and George C. Tsokos³, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
IKZF1 modulates PP2Ac expression through an intronic binding siteKamalpreet Nagpal1, Katsue Sunahori2, George C. Tsokos11Department of Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center,…
Abstract Number: 1062 • 2013 ACR/ARHP Annual Meeting
The Brief Index Of Lupus Damage As a Predictor Of Mortality In a Cohort Of Patients With Systemic Lupus Erythematosus
Stephanie Rush¹, Laura Trupin², Jinoos Yazdany² and Patricia P. Katz², ¹University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
The Brief Index of Lupus Damage as a Predictor of Mortality in a Cohort of Patients with Systemic Lupus Erythematosus Background/Purpose: To examine whether a…
Abstract Number: 607 • 2013 ACR/ARHP Annual Meeting
Venous Thromboembolic Disease Is Associated With Increased Length Of Stay and In-Hospital Mortality In Hospitalized SLE Patients: A Multi-State, Population-Based Study
Matthew Cascino¹, Laura Trupin¹, Sara Murray¹, Mary Margaretten², Edward H. Yelin³ and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are at increased risk for venous thromboembolism (VTE). However, there is limited population-based data on outcomes associated with…
Abstract Number: 2701 • 2013 ACR/ARHP Annual Meeting
Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T Cell Signaling
Alexandros P. Grammatikos¹, Debjani Ghosh² and Vasileios C. Kyttaris¹, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Microbiology and Immunology, The Brody School of Medicine, East Carolina University, Greenville, NC
Background/Purpose: Systemic Lupus Erythematosus (SLE) T cells display an aberrant response to CD3/ TCR stimulation. The CD3/TCR complex in SLE is characterized by the substitution…
Abstract Number: 1639 • 2013 ACR/ARHP Annual Meeting
GWAS In Hispanic and Latin American Individuals Enriched For Amerindian Ancestry Identifies a New Locus Associated With Systemic Lupus Erythematosus
Marta Eugenia Alarcon Riquelme¹, Julie T. Ziegler², Mary E. Comeau³, Elena Sanchez⁴, Bernado Pons-Estel⁵, Eduardo Acevedo⁶, Jorge Mariano Cucho⁶, Ignacio Garcia de la Torre⁷, Mario H. Cardiel⁸, Pedro Miranda⁹, Luis Cattogio¹⁰, Marco Maradiaga¹¹, Jorge Esquivel-Valerio¹², Jose F Moctezuma¹³, Mercedes Garcia¹⁴, Guillermo Berbotto¹⁵, Alejandra Babini¹⁶, Hugo Scherbarth¹⁷, Sergio Toloza¹⁸, Judith A James¹⁹, Teresa Tusie-Luna²⁰, John B Harley²¹, Raphael Zidovetski²², Carl Langefeldt² and Chaim O. Jacob²³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Wake Forest University Health Sciences, Winston-Salem, NC, ⁴King's College London, London, United Kingdom, ⁵Hospital Provincial de Rosario, Rosario, Argentina, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁷Hospital General de Occidente, Zapopan, Mexico, ⁸Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁹Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ¹⁰Hospital Italiano, Buenos Aires, Argentina, ¹¹Hospital General de Culiacán, Culiacan, Sinaloa, Mexico, ¹²Hospital Universitario Dr. José Eleuterio González, Universidad Autonoma de Nuevo León, Nuevo Leon, Mexico, ¹³Hospital General de Mexico, Mexico, Mexico, ¹⁴Hospital San Martin, La Plata, Argentina, ¹⁵Hospital Eva Peron, Granadero Baigorria, Argentina, ¹⁶Hospital Privado de Cordoba, Cordoba, Argentina, ¹⁷H.I.G.A. Oscar E. Alende, Mar del Plata, Argentina, ¹⁸Hospital San Juan Bautista, Catamarca, Argentina, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de México, and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²¹Childrens Hospital, Cincinnati, OH, ²²University of Southern California, Los Angeles, CA, ²³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE), a chronic autoimmune disease with a strong genetic component, exhibits a 9:1 female to male ratio and disproportionate impact on…
Abstract Number: 1066 • 2013 ACR/ARHP Annual Meeting
Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment
Cristina Drenkard¹, Charmayne M. Dunlop-Thomas², Gaobin Bao³ and S. Sam Lim⁴, ¹Department of Medicine, Emory University, Atlanta, GA, ²Medicine Rheumatology, Emory University, Atlanta, GA, ³Medicine, Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Depression can be found in 20-60% of SLE patients and has substantial impact on quality of life, disease outcomes and health care costs. Although…
Abstract Number: 610 • 2013 ACR/ARHP Annual Meeting
Disease Specific Quality Of Life Domains Are Impaired In Patients With Lupus Nephritis?
Meenakshi Jolly¹, Zineb Aouhab², Sergio Toloza³, Ana M. Bertoli⁴, Ivana Blazevik⁵, Luis M. Vila⁶, Ioana Moldovan⁷, Karina Marianne D. Torralba⁸, Arif Kaya⁹, Berna Goker¹⁰, Mehmet E. Tezcan¹¹, Seminur Haznedaroglu¹², Josiane Bourré-Tessier¹³, Ann E. Clarke¹⁴, D.J. Wallace¹⁵, Michael H. Weisman¹⁶ and Graciela S. Alarcon¹⁷, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine, John H Stroger Hospital, Chicago, IL, ³Hospital San Juan Bautista, Catamarca, Argentina, ⁴Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, ⁵University of Buenos Aires, Buenos Aries, Argentina, ⁶Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁷Loma Linda Univ Medical Center, Loma Linda, CA, ⁸Rheumatology/Int Med, USC Keck Schl of Medicine, Los Angeles, CA, ⁹Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ¹⁰Internal Medicine-Rheumatology, Gazi University, Ankara, Turkey, ¹¹Rheumatology, Dr. Lutfi Kirdar Kartal EA Hastanesi, Istanbul, Turkey, ¹²Internal Medicine-Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ¹³Rheumatology, McGill University, Montréal, QC, Canada, ¹⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ¹⁵Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁷Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Often systemic Lupus Erythematosus (SLE) patients with Lupus Nephritis (LN) require frequent visits with their health care providers, follow up, and exposure to immunosuppressive…
Abstract Number: 2703 • 2013 ACR/ARHP Annual Meeting
An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression
Jian Zhao¹, Brendan M. Giles², Rhonda L. Taylor³, Gabriel A. Yette², Kara M. Lough², Lawrence J. Abraham³, Hui Wu⁴, Patrick M. Gaffney⁵, Jennifer A. Kelly⁶, Kenneth M. Kaufman^7,8, John B. Harley^9,10, Carl D. Langefeld¹¹, Elizabeth E. Brown¹², Jeffrey C. Edberg¹³, Robert P. Kimberly¹⁴, Daniela Ulgiati³, Betty P. Tsao¹ and Susan A. Boackle¹⁵, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²University of Colorado School of Medicine, Aurora, CO, ³University of Western Australia, Perth, Western Australia, Australia, ⁴Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷U.S. Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁴Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁵Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by the production of antibodies to nuclear antigens, which form immune complexes that deposit in tissues and cause…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].